Close Menu

More articles about Research & Discovery

Providing further evidence that scientists from diverse disciplines are seeking to apply proteomics techniques to their research, a symposium earlier this month sponsored by the NIH s National Center for Toxicogenomics featured prominent players from the field of proteomics, including Denis Hochstrasser, a founder of GeneProt, and Emanuel Petricoin, a co-director of the joint NCI-FDA clinical proteomics program Subscribers: click headline for more

Subscribers: click headline for more

MDS Proteomics plans to go through with an initial public offering next year to acquire additional funding, the company s new CFO said last week Subscribers: click headline for more

Subscribers: click headline for more

Subscribers: click headline for more

Rounding out the selection of protein analysis equipment for its US proteomics factory, GeneProt has chosen Micromass to install Q-TOF mass spectrometers and liquid chromatography systems valued at $20 million in its North Brunswick, NJ, facility, the companies said last week. In addition, Micromass will make an equity investment of up to $10 million in GeneProt Subscribers: click headline for more

In the past year and a half, for-profit scientific publishers have launched two new research journals devoted to proteomics: Proteomics and Proteome. The latter lasted about four months before Springer -- under new Bertelsmann managers -- pulled the plug Subscribers: click headline for more

In support of its claim to have a hand in both proteomics technology development and discovery, Proteome Systems has signed a research partnership with Eukarion, a privately-held drug company, that will give Proteome Systems a stake in the profits from any drugs developed through the collaboration.

With the number of protein structures growing exponentially, an increasing number of companies are focusing their efforts on structure-based drug design. One of the latest additions is Plexxikon of Berkeley, Calif., founded in December of 1999 by a team of scientists with expertise in cell signaling proteins and their potential as drug targets Subscribers: click headline for more

Subscribers: click headline for more

Like many large pharmaceutical and biotechnology companies, Genentech has made a point of delving into proteomics as a new approach to discovering potential drug targets and therapeutic proteins. The South San Francisco-based company has developed platforms for implementing differential proteomics experiments and mapping protein interactions, using primarily off-the-shelf multi-dimensional chromatography and mass spectrometry. Subscribers: click headline for more

While states such as California and Massachusetts spring more immediately to mind when it comes to homes for proteomics and other biotechnology companies, Michigan, the land of great lakes, great location, has embarked on an ambitious program to prove that proteomics can thrive in the heartland too. Subscribers: click headline for more

Hoping to find new markets in proteomics and other life science applications, the Canadian National Research Council (NRC) has spun-off a company to commercialize a technology called high-field asymmetric waveform ion mobility mass spectrometry (FAIMS), the NRC said last week.. Subscribers: click headline for more

Subscribers: click headline for more

Subscribers: click headline for more

Applied Biosystems has broadened the scope of its technology partnership with Northeastern University chemist Barry Karger, the company said last week Subscribers: click headline for more

Hailing from Morgantown, West Virginia, month-old startup Protea Biosciences hopes to be the first proteomics company to bring biotech fame to this college town Subscribers: click headline for more

Caprion Pharmaceuticals has secured at least $18 million in loans from the Quebec government to supplement the $45 million it has raised in private capital markets, the Montreal-based firm said last week Subscribers: click headline for more

Researchers at the Mount Sinai School of Medicine have agreed to license a subset of AxCell Biosciences ProChart database of protein-protein interactions involving the WW domain family, the company said last week Subscribers: click headline for more

Large Scale Biology Corporation

Premium

Subscribers: click headline for more

Pages

Bloomberg Law writes that the Genetic Information Nondiscrimination Act may work better as a privacy, rather than anti-discrimination, law.

TechCrunch reports that Linda Avey has a new personal genomics startup that's focusing on India.

A new report finds that though the US has increased its activity in science and engineering, its global share of that activity has fallen in some areas, according to Inside Higher Ed.

In Nature this week: genomic analysis of rapeseed, universal target enrichment method for metagenomic sequencing, and more.